Below are upcoming trade shows and conferences that AnaBios will be attending. Be sure to check back often to view our upcoming events. Want to schedule a meeting with an AnaBios representative? Email us at

AnaBios is proud to sponsor the 2022 HFpEF Drug Discovery & Development Summit in Boston, MA. In addition, we are sponsoring a presentation, “Human Ex-Vivo Drug Discovery in HFpEF Donor Hearts,” presented by Dr. Najah Abi-Gerges. Click here to receive a 10% discount when registering for the event. 

AnaBios Vice President of Research & Development Dr. Najah Abi-Gerges will present new human spinal cord and cardiomyocyte research at the Japan Safety Pharmacology Conference on February 4th.

In our next webinar, Dr. Daniela Menichella, Associate Professor of Neurology and Pharmacology at Northwestern University, will discuss how an unbiased single-cell transcriptional profiling approach has revealed the complete gene expression profile of molecularly distinct dorsal root ganglia (DRG) neuronal subtypes, along with the specific genes differentially expressed in individual neuronal subtypes under diabetic and non-diabetic conditions in the High-Fat-Diet mouse model of painful diabetic neuropathy (PDN). Click here to register. 

Dr. Najah Abi-Gerges, VP of Research & Development, will present new data from AnaBios’ unique human adult primary cardiomyocyte and spinal cord assays for safety testing at the upcoming 2022 Society of Toxicology Annual Meeting.  Using proprietary methods, AnaBios prepares high-quality cardiomyocytes and organotypic spinal cord cultures for physiology assays on a weekly basis.  Several new platforms from AnaBios will be presented including: 24-hour incubation with human cardiomyocytes, cardiomyocytes from juvenile donors for pediatric cardiac safety, heart slice preparation, precision cut lung slices and spinal cord slices for the assessment of CNS toxicity. Click here to register.